Not surprisingly, given rather positive briefing documents from US Food and Drug Administration staffers earlier this week, the agency’s Vaccines and Related Biological Products Advisory Committee gave the thumbs up for COVID-19 vaccine Janssen to be approved for emergency use authorization (EUA) following deliberations on Friday.
The non-binding decision, which was adopted by a vote of 22 to 0 by the FDA’s AdCom, comes as the Biden administration works to ramp up the supply of vaccine doses and get Americans vaccinated as quickly as possible, as the US death toll from COVID-19 surpassed 500,000 in the past week.
The vote compares to a 17-4 vote for the first authorized COVID-19 vaccine, from Pfizer (NYSE: PFE) and Germany’s BioNTech (Nasdaq: BNTX), and a 21-0 vote, with one abstention, for Moderna’s (Nasdaq: MRNA) vaccine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze